ESMO Media Releases

The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, has announced the recipients of its four distinguished annual awards, to be presented at the ESMO 2017 Congress (8-12 September, Madrid, Spain).

For patients with colorectal cancer that has metastasised to the liver, having a primary tumour on the left side, as opposed to the right side of the colon, is known to be a significant advantage in terms of treatment response.

A new study shows that so-called “liquid biopsies” may not only sound an early alert that a treatment’s effect is diminishing, but may also help explain why -sometimes offering clues about what to do next.

The benefits of a “Mediterranean diet” (MD) are well-known when it comes to colorectal protection, but it’s hard to know specifically what elements of the diet are the healthiest.

ESMO announced today that the President for 2020-2021 is Professor Solange Peters, MD, PhD, head of the Medical Oncology Service, Chair of Thoracic Oncology, Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

The Impact Factor for Annals of Oncology has risen to 11.855, according to the latest Journal Citation Reports®* (1).  The journal now sits 10th in the field, within the top 5% of oncology titles.

Around 3,500 oncology professionals and researchers from around the world will learn about the latest advances in the field at the 19^th ESMO World Congress on Gastrointestinal Cancer taking place in Barcelona, Spain, from 28 June to 1 July 2017

ESMO is pleased to announce the ESMO 2019 Annual Congress will take place at the Fira Barcelona, Spain from 27 September to 1 October 2019

The count of submitted abstracts this year has marked a 13% increase since ESMO 2016, with 3,250 abstracts received, 92 of them earmarked for submission as Late Breaking Abstracts...

ESMO welcomes the adoption of the Resolution on Cancer prevention and control in the context of an integrated approach during the 70th World Health Assembly (WHA), May 22 to 31 in Geneva, Switzerland

A late breaking subanalysis of the phase III CONVERT trial to be presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo-radiotherapy of small cell lung cancer (SCLC)

White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research to be presented at the European Lung Cancer Conference